Aims: A specific composition of gut microbiota can increase insulin resistance. The aim of this pilot study was to find differences between pregnant women with GDM and controls in terms of gut microbiota composition during the 3rd trimester.

Methods: This study was carried out in 20 women, 10 with GDM (IADPSG criteria) (Age 36.2±4.4 years; BMI 24.6 (21.4-26.8)Kg/m2) and 10 controls (Age 32.0±2,7 years; BMI 22.1 (19-24.1)Kg/m2) at the 34-36th week of gestation, when fecal samples were collected. Exclusion criteria: antibiotics/probiotics/symbiotics/metformin use during gestation, GADAb+, twin pregnancy, IBD. Genera and species were detected by using a Next Generation Sequencing technology (Ion Torrent Personal Genome Machine). Statistics: SPSS.

Results: the two groups were well matched a part from age (p=0.04). No difference in weight gain (GDM 12.2±4.9; Controls 12.4±5.1 Kg). With regard to the primary aim we found an higher Relative Abundance of Bacteroides caccae, massiliensis, thetaiotaomicron (respectively 87%, 89,4%, 91%; p<0.05) together with a reduction of Bacteroides vulgatus, Eubacterium eligens, Lactobacillus rogosae, Prevotella copri (respectively 27,4%, 41,5%, 6%, 25%; p<0,05) in women with GDM. No difference in biodiversity indexes.

Conclusion: the recognition of a “GDM-related” gut microbiome could lead to symbiotics/probiotics formula for GDM prevention and/or treatment.


C. Festa: Consultant; Self; Menarini Group. Other Relationship; Self; Merck Sharp & Dohme Corp.. V.D. Corleto: None. M. Toscano: None. O. Bitterman: None. L. Drago: None. A. Napoli: Other Relationship; Self; Merck Sharp & Dohme Corp..

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at